Symyx Technologies has announced it has joined Safe-Biopharma Association, which created the Safe-Biopharma digital identity and signature standard for the pharmaceutical and healthcare industries.
The membership enables Symyx to implement the Safe-Biopharma digital signature standard for records signing to safeguard critical scientific data.
The membership also enables Symyx to participate in Safe-Biopharma working groups to further secure the electronic laboratory environment.
Symyx customers can utilise Safe-Biopharma digital signature within Symyx Notebook, an enterprise electronic lab notebook (ELN) that supports multiple scientific disciplines including biology, chemistry, formulations development, and analytical laboratories where protecting intellectual property, avoiding patent interference, and satisfying regulatory agency submissions are critical activities.
'Applying a Safe-Biopharma digital signature to mission-critical documents establishes a robust and defensible record of invention for R+D companies needing to protect and defend their intellectual properties,' said Mollie Shields-Uehling, president and chief executive, Safe-Biopharma Association.
'Our industry-standard protocol helps mitigate the legal, regulatory and business risks associated with electronic transactions, while facilitating interoperability between disparate information systems,' she added.
Symyx Notebook enables scientists to plan, execute and analyse experiments across the spectrum of research, development and analytical QC labs while providing data and document workflow transparency to life sciences and chemicals businesses.
Symyx Notebook experimental entries provide key documentation for the intellectual properties of Symyx's pharmaceutical and biotechnology customers, establishing the date of record for invention, which is vital to patent claims and patent defence litigation.
The Symyx Notebook platform also enables scientists to connect with their existing laboratory instrumentation and software tools to gain compliance protection without redeveloping operational business practices.
'By aligning ourselves with Safe-Biopharma, Symyx continues to ensure that sensitive intellectual property is securely captured and managed,' said Dr Trevor Heritage, president of Symyx's software business unit.
Symyx scientific information management enables scientists to design, execute, analyse and report experimental results.
Symyx microscale, parallel experimentation enables a single scientist to explore a broad experimental space and develop comprehensive data sets in days.
Symyx contract research delivers these features on a project basis and can allow companies to increase R+D productivity, agility and flexibility.
